主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
VKTX
#1285
Viking Therapeutics, Inc
33.8
4
+6.28%
版块:
基础:
利润货币:
日范围
年范围
日变化
+6.28%
每月变动
+7.46%
6个月变化
+25.94%
年变化
+20.43%
前一天收盘价
31.8
4
Open
33.8
4
Bid
Ask
Low
33.8
4
High
33.8
4
交易量
112
市场
股票
医疗保健
VKTX
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Dividends per share
—
—
—
—
—
—
—
Dividend yield %
—
—
—
—
—
—
—
Payout ratio %
—
—
—
—
—
—
—
新闻
Lilly's GLP-1 Blockbusters Drive 2025 Revenue Surge: What's Ahead?
Lilly vs. Novo Nordisk: Obesity Drug Giants' Face-Off in 2026
American Express, Oracle among market cap stock movers on Monday
Novo Nordisk Dives As Next-Gen Obesity Drug Lags Eli Lilly's Kingpin
Structure Therapeutics: The Dark Horse Has Taken The Lead - But Is It Enough? (GPCR)
Can LLY's Next-Gen Obesity Pipeline Sustain Growth Amid Competition?
Hims & Hers Faces New Hurdle In Weight-Loss Brawl With Novo Nordisk
NVO Crashes 21% in a Month: Is This an Indication to Sell the Stock?
Viking Therapeutics: Full-Speed Ahead (NASDAQ:VKTX)
Viking: Buyers Quietly Accumulating On Obesity Drugs Launch Potential (NASDAQ:VKTX)
Cisco and Micron among market cap stock movers on Thursday
How to Play Eli Lilly Stock Following a Robust Q4 Earnings Report